BDBM50571663 CHEMBL4855866::US20250019371, Compound 19

SMILES CC(C)(Oc1cccc(c1)N1CCCC(C1)C(=O)N(Cc1ccc(cc1)-c1cccs1)C1CC1)C(=O)NS(=O)(=O)C1CC1

InChI Key InChIKey=NWWAOVBKNDIRFQ-UHFFFAOYSA-N

Data  2 KI  2 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 50571663   

TargetB-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

Curated by ChEMBL
LigandPNGBDBM50571663(CHEMBL4855866 | US20250019371, Compound 19)
Affinity DataIC50: 2.30E+4nMAssay Description:Inhibition of full length C-terminal 6-His-tagged beta-catenin (1 to 781 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3)-N-termin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/20/2022
Entry Details Article
PubMed
TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571663(CHEMBL4855866 | US20250019371, Compound 19)
Affinity DataIC50: 3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetB-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

Curated by ChEMBL
LigandPNGBDBM50571663(CHEMBL4855866 | US20250019371, Compound 19)
Affinity DataKi:  1.90E+4nMAssay Description:Inhibition of full length C-terminal 6-His-tagged beta-catenin (1 to 781 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3)-N-termin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/20/2022
Entry Details Article
PubMed
TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571663(CHEMBL4855866 | US20250019371, Compound 19)
Affinity DataKi: <3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent